CompletedNot Applicable

Pharmacodynamic Effects of Cangrelor in ACS or CCS Patients Undergoing PCI (POMPEII Registry)

Italy150 participantsStarted 2021-03-16

Plain-language summary

This prospective registry was designed to carefully investigate the pharmacodynamic (PD) effects of cangrelor in all patients undergoing percutaneous coronary intervention (PCI).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All adult patients undergoing PCI and receiving cangrelor administration will be eligible for inclusion in the study. Exclusion Criteria: * only those not providing consent to blood/data collection will be excluded.

What they're measuring

Inhibition of platelet activity (IPA, %) with LTA-ADP 20 µmol/l

Timeframe: 30 minutes

Trial details

NCT IDNCT04790032

SponsorFederico II University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-07-01

View on ClinicalTrials.gov More Percutaneous Coronary Intervention trials